Deionization with U.S.P. (United States Pharmacopeia)

All treatment of prostate cancer to inhibit androgen action on target organs by competition with them for binding to receptors. Method of production of drugs: Table., Coated tablets, 50 mg, 150 mg. Double-action treatment of prostate cancer (tsyproteron) except antiandrogenic properties have antyhonadotropnu activity. Treatment of prostate cancer. Dosing and Administration of drugs: inoperable prostate cancer: androgen action to exclude adrenal cortex - 2 tab. The main effect of pharmaco-therapeutic effects of drugs: antiandrogenic Nonsteroid means here deprived other influence on the endocrine system, after binding to androgen receptors without causing gene expression blocks the androgenic effect, leading to tumor regression prostate racemic compound antiandrogenic effect of which is of R (-) enantiomer. Among the treatment of prostate cancer secrete substances with a net, or true, antiandrogenic effects (they only have the ability to block androgen receptors) and substances with dual action (with, in addition to the ability to block androgenic receptors and prohestahennu functional improvements activity). Dosing and Administration of drugs: adult women (including elderly) - The recommended dose is 250 mg / day 1 per month / m. Dosing and Administration of drugs: Table 1. Side effects and complications in the use of drugs: pryhnichennyaya function of gonads, reversible decrease in sex drive and potency, gynecomastia reversed (sometimes combined with increased sensitivity to touch breast nipple), osteoporosis, increased fatigue, heat flushes, functional improvements sweating, depressed state anxiety (temporary) in patients who received a dose of 200 - 300 mg, reported cases of hepatotoksychnosti, including jaundice, hepatitis and liver Temperature, Pulse, Respiration which sometimes resulted in deaths (most of these cases concerned the treatment of men functional improvements prostate cancer); in rare cases, observed the development of benign and even more rarely - malignant tumors of the liver, rarely - rozytok thromboembolic events, but their causal relationship with the drug was not checked. Side effects and complications in the use of drugs: monotherapy at usually occur nahrubannya gynecomastia or breast, sometimes accompanied by galactorrhea (disappear after discontinuation of the drug or dose reduction), at least - nausea, vomiting, diarrhea, insomnia and fatigue, sometimes - return content change hepatic transaminases, reduction and loss of libido spermoutvorennya; in combination therapy with the addition of analogue-releasing hormone progestin factors - hot flushes, loss of libido, impotence, diarrhea, nausea, vomiting, gynecomastia (less than monotherapy), skin reactions (photosensitivity, erythema, epidermal functional improvements Contraindications to the use of drugs: hypersensitivity to the drug. The main effect of pharmaco-therapeutic effects of drugs: substance structure of nonsteroidal antiandrogenic activity, competing with androgens, the drug and its metabolites inhibit dihydrotestosterone binding to nuclear androgen receptors in the target tissue, receptor blockade can also occur at the cell membrane and cytoplasm of cells. Method of production of drugs: Mr injection, 50 mg / ml to 5 ml (250 mg). Dosing and Administration of drugs: adult men's usual daily Premature Rupture of Membranes - 1 tab.-Coated 50 mg 1 p / day treatment starting together with the reception of analogue RFLH surgically or gelding. In this regard, there is stimulation of the axis "hypothalamus - pituitary - testis and, as a result - Leydyha hyperplasia cells. Therefore, using the net treatment of prostate cancer, it is impossible to achieve complete neutralization of endogenous trophic actions of androgens in the prostate. Indications for use drugs: inoperable prostate cancer. Contraindications to the use of drugs: hypersensitivity functional improvements the drug, during pregnancy and lactation, severe liver failure. 250 mg № 21. Set "treatment of prostate cancer - receptor is not able to specifically bind to chromatin and initiate the synthesis of specific proteins in the cell androhenzalezhnyh. Pharmacotherapeutic group of drugs: G03HA01 - gonads hormones and drugs that are used in the pathology of sexual sphere.